Region-specific effects of nicotine on brain activity: A pharmacological MRI study in the drug-näve rat

Neuropsychopharmacology

Volumn 31, Issue 8, 2006, Pages 1690-1703

  Gozzi, Alessandro ^a   Schwarz, Adam ^a   Reese, Torsten ^a   Bertani, Simone ^a   Crestan, Valerio ^a   Bifone, Angelo ^a  

^a GSK   (Italy)

Author keywords

A 85380; Alpha 7; CBV; fMRI; Nicotine; Rat

Indexed keywords

3 [3 (2 AZETIDINYLMETHOXY)] 5 IODOPYRIDINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; HYPERTENSIVE FACTOR; ISOPROTEIN; MECAMYLAMINE; N (1 AZABICYCLO[2.2.2]OCT 3 YL)[5 (2 PYRIDYL)THIOPENE 2 CARBOXAMIDE]; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN BLOOD VOLUME; BRAIN MAPPING; BRAIN REGION; CARDIOVASCULAR RESPONSE; CINGULATE GYRUS; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; HIPPOCAMPUS; INSULA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROVOCATION TEST; RAT; RECEPTOR AFFINITY; TISSUE STRUCTURE;

ANIMALS; BRAIN; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; MAGNETIC RESONANCE IMAGING; MALE; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 33746275148     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300955     Document Type: Article

References (108)

1. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J (1998). Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15: 67-74.
2. Angel A (1993). Central neuronal pathways and the process of anaesthesia. Br J Anaesth 71: 148-163.
3. 3H]nicotine binding sites in human brain. J Neurochem 50: 1243-1247.
4. Buisson B, Bertrand D (2002). Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 23: 130-136.
5. Bunnelle WH, Decker MW (2003). Neuronal nicotinic acetylcholine receptor ligands as potential analgesics. Expert Opin Ther Patents 13: 1003-1021.
6. Calderan L, Chiamulera C, Marzola P, Fabene PF, Fumagalli GF, Sbarbati A (2005). Sub-chronic nicotine-induced changes in regional cerebral blood volume and transversal relaxation time patterns in the rat: a magnetic resonance study. Neurosci Lett 377: 195-199.
7. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O et al (1997). Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38: 389-398.
8. Chiodini FC, Tassonyi E, Hulo S, Bertrand D, Muller D (1999). Modulation of synaptic transmission by nicotine and nicotinic antagonists in hippocampus. Brain Res Bull 48: 623-628.
9. Cilia J, Cluderay JE, Robbins MJ, Reavill C, Southam E, Kew JN et al (2005). Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. Psychopharmacology (Berl) 182: 214-219.
10. Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A (1985). Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J Neurosci 5: 1307-1315.
11. Corrigall WA (1991). Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86: 507-510.
12. Cox RW, Hyde JS (1997). Software tools for analysis and visualization of FMRI Data. NMR Biomed 10: 171-178.
13. Dani JA, Heinemann S (1996). Molecular and cellular aspects of nicotine abuse. Neuron 16: 905-908.
14. De Filippi G, Broad LM, Zwart R, Baldwinson T, Felthouse C, McPhie G et al (2002). Pharmacological Characterisation and In Vitro physiological Effects of New 7 Nicotinic Acetylcholine Receptor Agonists, Vol 137. Society for Neuroscience (Online): Washington, DC, p 1.
15. Edvinsson L, Krause DN (2002). Cerebral Blood Flow and Metabolism. Lippincott Williams & Wilkins: Philadelphia.
16. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992). A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.
17. Franks NP, Lieb WR (1998). Which molecular targets are most relevant to general anaesthesia? Toxicol Lett 100-101: 1-8.
18. Genovese CR, Lazar NA, Nichols T (2002). Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage 15: 870-878.
19. Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA (2001). Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′-14C]nicotine. Drug Metab Dispos 29: 645-651.
20. Giniatullin RA, Sokolova EM, Di Angelantonio S, Skorinkin A, Talantova MV, Nistri A (2000). Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: an electrophysiological and modeling study. Mol Pharmacol 58: 778-787.
21. Gotti C, Fornasari D, Clementi F (1997). Human neuronal nicotinic receptors. Prog Neurobiol 53: 199-237.
22. Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A (2005a). Functional imaging of nicotine and selective nicotinic acetylcholine receptor agonists in the anesthetised rat. Second UK Nicotinic Receptor Club Meeting, Vol P-2, Harlow, UK, p 19.
23. Gozzi A, Schwarz AJ, Reese T, Bertani S, Bifone A (2005c). Functional imaging of nicotine in the anaesthetised rat. Book of abstracts: 13th Annual Meeting of the International Society of Magnetic Resonance in Medicine, Vol P-1508. Miami, p 307.
24. Gozzi A, Schwarz AJ, Reese T, Crestan V, Bertani S, Turrini G et al (2005b). Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat. J Neurosci Methods 142: 115-124.
25. Grunwald F, Schrock H, Kuschinsky W (1987). The effect of an acute nicotine infusion on the local cerebral glucose utilization of the awake rat. Brain Res 400: 232-238.
26. Grunwald F, Schrock H, Kuschinsky W (1991). The influence of nicotine on local cerebral blood flow in rats. Neurosci Lett 124: 108-110.
27. Guitton D (1992). Control of eye-head coordination during orienting gaze shifts. Trends Neurosci 15: 174-179.
28. Holladay MW, Dart MJ, Lynch JK (1997). Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40: 4169-4194.
29. Hommer DW (1999). Functional imaging of craving. Alcohol Res Health 23: 187-196.
30. Hyder F, Kennan RP, Kida I, Mason GF, Behar KL, Rothman D (2000). Dependence of oxygen delivery on blood flow in rat brain: a 7 tesla nuclear magnetic resonance study. J Cereb Blood Flow Metab 20: 485-498.
31. Itier V, Bertrand D (2001). Neuronal nicotinic receptors: from protein structure to function. FEBS Lett 504: 118-125.
32. Jenkins BG, Chen Y-CI, Mandeville JB (2003). Pharmacological magnetic resonance imaging (phMRI). In: van Bruggen N, Roberts T (eds). Biomedical Imaging in Experimental Neuroscience. CRC Press: New York. pp 155-209.
33. Kauer JA (2005). Neuroscience: a home for the nicotine habit. Nature 436: 31-32.
34. Kiba H, Jayaraman A (1994). Nicotine induced c-fos expression in the striatum is mediated mostly by dopamine D1 receptor and is dependent on NMDA stimulation. Brain Res Mol Brain Res 23: 1-13.
35. Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J (2000). Human [alpha]6 AChR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology 39: 2570-2590.
36. Laviolette SR, Van der Kooy D (2004). The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5: 55-65.
37. Le Novere N, Zoli M, Lena C, Ferrari R, Picciotto MR, Merlo-Pich E et al (1999). Involvement of alpha6 nicotinic receptor subunit in nicotine-elicited locomotion, demonstrated by in vivo antisense oligonucleotide infusion. NeuroReport 10: 2497-2501.
38. Lee JG, Hudetz AG, Smith JJ, Hillard CJ, Bosnjak ZJ, Kampine JP (1994). The effects of halothane and isoflurane on cerebrocortical microcirculation and autoregulation as assessed by laser-doppler flowmetry. Anesthesia Analgesia 79: 58-65.
39. Levin ED (2002). Nicotinic receptor subtypes and cognitive function. J Neurobiol 53: 633-640.
40. Levin ED, Bradley A, Addy N, Sigurani N (2002). Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109: 757-765.
41. Levin ED, Rezvani AH (2002). Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 1: 423-431.
42. Levin ED, Simon BB (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138: 217-230.
43. Liu X, Koren AO, Yee SK, Pechnick RN, Poland RE, London ED (2003). Self-administration of 5-iodo-A-85380, a beta2-selective nicotinic receptor ligand, by operantly trained rats. NeuroReport 14: 1503-1505.
44. London ED, Connolly RJ, Szikszay M, Wamsley JK, Dam M (1988a). Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci 8: 3920-3928.
45. London ED, Dam M, Fanelli RJ (1988b). Nicotine enhances cerebral glucose utilization in central components of the rat visual system. Brain Res Bull 20: 381-385.
46. London ED, Fanelli RJ, Kimes AS, Moses RL (1990). Effects of chronic nicotine on cerebral glucose utilization in the rat. Brain Res 520: 208-214.
47. Lukas RJ, Changeux JP, le Novere N, Albuquerque EX, Balfour DJ, Berg DK et al (1999). International Union of Pharmacology. XX. Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and Their Subunits. Pharmacol Rev 51: 397-401.
48. Mandeville JB, Marota JJA, Kosofsky BE, Keltner JR, Weissleder R, Rosen B et al (1998). Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39: 615-624.
49. Marota JJA, Mandeville JB, Weisskoff R, Moskowitz MA, Rosen B, Kosofsky BE (2000). Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. NeuroImage 11: 13-23.
50. Marshall DL, Redfern PH, Wonnacott S (1997). Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68: 1511-1519.
51. Mathieu-Kia AM, Pages C, Besson MJ (1998). Inducibility of c-Fos protein in visuo-motor system and limbic structures after acute and repeated administration of nicotine in the rat. Synapse 29: 343-354.
52. Matta SG, Foster CA, Sharp BM (1993). Nicotine stimulates the expression of cFos protein in the parvocellular paraventricular nucleus and brainstem catecholaminergic regions. Endocrinology 132: 2149-2156.
53. McClernon FJ, Gilbert J (2004). Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. Nicotine Tobacco Res 6: 941-959.
54. McGehee DS, Role LW (1995). Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57: 521-546.
55. Mogg AJ, Jones FA, Pullar IA, Sharples CGV, Wonnacott S (2004). Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47: 848-859.
56. Mogg AJ, Whiteaker P, McIntosh JM, Marks M, Collins AC, Wonnacott S (2002). Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII- sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 302: 197-204.
57. Morita H, Nemoto EM, Bleyaert AL, Stezoski SW (1977). Brain blood flow autoregulation and metabolism during halothane anesthesia in monkeys. Am J Physiol 2: H670-H676.
58. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS et al (2000). 5-Iodo-A-85380, an alpha 4beta 2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-649.
59. Navarro HA, Xu H, Zhong D, Abraham P, Carroll FI (2002). In vitro and in vivo characterization of [125I]iodomethyllycaconitine in the rat. Synapse 44: 117-123.
60. Nguyen TV, Brownell A-L, Chen Y-CI, Livni E, Coyle JT, Rosen B et al (2000). Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 36: 57-65.
61. Nisell M, Nomikos GG, Chergui K, Grillner P, Svensson TH (1997). Chronic nicotine enhances basal and nicotine-induced Fos immunoreactivity preferentially in the medial prefrontal cortex of the rat. Neuropsychopharmacology 17: 151-161.
62. Ogawa S, Menon RS, Tank DW, Kim SG, Merkle H, Ellermann JM et al (1993). Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J 64: 803-812.
63. Oldendorf WH (1971). Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 221: 1629-1639.
64. O'Neill MJ, Moore NA, McKinzie DL, Keenan M, Wishart G, Shannon HE et al (2002). Behavioural profiling of two potent alpha 7 nicotinic acetylcholine receptor agonists, Vol 137. Society for Neuroscience (Online): Washington DC, p 1.
65. Pang Y, Kiba H, Jayaraman A (1993). Acute nicotine injections induce c-fos mostly in non-dopaminergic neurons of the midbrain of the rat. Brain Res Mol Brain Res 20: 162-170.
66. Papke RL, Sanberg PR, Shytle RD (2001). Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297: 646-656.
67. Paterson D, Nordberg A (2000). Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111.
68. Paxinos G, Watson C (1998). The Rat Brain in Stereotactic Coordinates. Academic Press: San Diego.
69. Picciotto MR (2003). Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24: 493-499.
70. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL (2001). Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92: 89-108.
71. Quick MW, Lester RA (2002). Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457-478.
72. Reavill C, Stolerman IP (1990). Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 99: 273-278.
73. Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A et al (2000). Regional brain activation by bicuculline visualized by functional magnetic resonance imaging, time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed 13: 43-49.
74. Ren T, Sagar SM (1992). Induction of c-fos immunostaining in the rat brain after the systemic administration of nicotine. Brain Res Bull 29: 589-597.
75. Rezvani AH, Levin ED (2001). Cognitive effects of nicotine. Biol Psychiatry 49: 258-267.
76. Romanelli MN, Gualtieri F (2003). Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications. Med Res Rev 23: 393-426.
77. Rudolph U, Antkowiak B (2004). Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 5: 709-720.
78. Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A et al (2002). Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16: 189-200.
79. Schilstrom B, De Villiers S, Malmerfelt A, Svensson TH, Nomikos GG (2000). Nicotine-induced Fos expression in the nucleus accumbens and the medial prefrontal cortex of the rat: role of nicotinic and NMDA receptors in the ventral tegmental area. Synapse 36: 314-321.
80. Schilstrom B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH (2003). Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol 6: 1-11.
81. Schwarz A, Gozzi A, Reese T, Bertani S, Crestan V, Hagan J et al (2004a). Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 54: 1-10.
82. Schwarz A, Whitcher B, Reese T, Gozzi A, Bifone A (2005). Group-level data-driven phMRI analysis. Book of Abstracts: Thirteenth Annual Meeting of the International Society of Magnetic Resonance in Medicine, Vol 13. Miami, p 157.
83. Schwarz AJ, Reese T, Gozzi A, Bifone A (2003). Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 21: 1191-1200.
84. Schwarz AJ, Zocchi A, Reese T, Gozzi A, Garzotti M, Varnier G et al (2004b). Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. Neuroimage 23: 296-304.
85. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993). Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596-604.
86. Seppa T, Salminen O, Moed M, Ahtee L (2001). Induction of Fos-immunostaining by nicotine and nicotinic receptor antagonists in rat brain. Neuropharmacology 41: 486-495.
87. Shoaib M, Lowe AS, Williams SC (2004). Imaging localised dynamic changes in the nucleus accumbens following nicotine withdrawal in rats. Neuroimage 22: 847-854.
88. Sparks DL (1986). Translation of sensory signals into commands for control of saccadic eye movements: role of primate superior colliculus. Physiol Rev 66: 118-171.
89. Steckler T, Drinkenburg WHIM, Sahgal A, Aggleton JP (1998). Recognition memory in rats - II. Neuroanatomical substrates. Neurobiol 54: 313-332.
90. Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D (2002). The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 57: 133-150.
91. Tong X, Dawson LA (2005). Effects of an alpha7 receptor agonist on forebrain neurochemistry: a microdialysis study. Second UK Nicotinic Receptor Club Meeting, Vol P-32, Harlow, UK, p 49.
92. Tribollet E, Bertrand D, Marguerat A, Raggenbass M (2004). Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience 124: 405-420.
93. Tuor UI, McKenzie E, Tomanek B (2002). Functional magnetic resonance imaging of tonic pain and vasopressor effects in rats. Magn Reson Imaging 20: 707-712.
94. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004). AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 172: 375-383.
95. Vaupel DB, Mukhin AG, Kimes AS, Horti AG, Koren AO, London ED (1998). In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. NeuroReport 9: 2311-2317.
96. Vaupel DB, Tella SR, Huso DL, Mukhin AG, Baum I, Wagner WO et al (2005). Pharmacology, toxicology and radiation dosimetry evaluation of [123I]5-I-A-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humans. Drug Dev Res 58: 149-168.
97. Violet JM, Downie DL, Nakisa RC, Lieb WR, Franks NP (1997). Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics. Anesthesiology 86: 866-874.
98. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J et al (1989). Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol 284: 314-335.
99. Wadsworth G, Stean T, Stratton S, Upton N (2005). Behavioural consequences of mecamylamine in rats: a model of alpha7 nicotinic acetylcholine receptor function. Second UK Nicotinic Receptor Club Meeting, Vol P-31, Harlow, UK, p 48.
100. Wang S, Wang H, Niemi-Junkola U, Westby GW, McHaffie JG, Stein BE et al (2000). Parallel analyses of nociceptive neurones in rat superior colliculus by using c-fos immunohistochemistry and electrophysiology under different conditions of anaesthesia. J Comp Neurol 425: 599-615.
101. Ward JM, Cockcroft VB, Lunt GG, Smillie FS, Wonnacott S (1990). Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett 270: 45-48.
102. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR (1994). Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 31: 601-610.
103. Whitcher B, Schwarz AJ, Barjat H, Smart SC, Grundy RI, James MF (2005). Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. Neuroimage 24: 281-295.
104. Williams M, Robinson JL (1984). Binding of the nicotinic cholinergic antagonist, dihydro-beta-erythroidine, to rat brain tissue. J Neurosci 4: 2906-2911.
105. Wonnacott S, Sharples CG (2001). Neruonal nicotinic receptors. Tocris Rev 19: 1-12.
106. Wonnacott S, Sidhpura N, Balfour DJ (2005). Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 5: 53-59.
107. Young WL, Barkai AI, Prohovnik I, Nelson H, Durkin M (1991). Effect of PaCO2 on cerebral blood flow distribution during halothane compared with isoflurane anaesthesia in the rat. Br J Anaesth 67: 440-446.
108. Zaharchuk G, Mandeville JB, Bogdanov Jr AA, Weissleder R, Rosen BR, Marota JJ (1999). Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 30: 2197-2204.